Cargando…

Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer

The aim of this study was to evaluate the predictive value of the polymorphism Glutathione S-transferase P1 (GSTP1) Ile(105)Val on oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qing-Fang, Yao, Ru-Yong, Liu, Ke-wei, Lv, Hong-Ying, Jiang, Tao, Liang, Jun
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877230/ https://www.ncbi.nlm.nih.gov/pubmed/20514304 http://dx.doi.org/10.3346/jkms.2010.25.6.846

Ejemplares similares

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
por: Deng, Xunwei, et al.
Publicado: (2020)

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Zaanan, Aziz, et al.
Publicado: (2014)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
por: Stoehlmacher, J, et al.
Publicado: (2004)

MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer
por: Sun, Ning, et al.
Publicado: (2009)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
por: Mori, Ryutaro, et al.
Publicado: (2012)

Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism
por: KITADE, HIRONORI, et al.
Publicado: (2014)

Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases
por: Hajdinák, Péter, et al.
Publicado: (2020)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013)

Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis
por: Fang, Yuan, et al.
Publicado: (2020)

S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma
por: Xia, Yu, et al.
Publicado: (2022)

Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy
por: Feng, Daofu, et al.
Publicado: (2015)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer
por: Ma, Jie, et al.
Publicado: (2017)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy
por: Deng, Xiaheng, et al.
Publicado: (2015)

Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis
por: Pu, Feifei, et al.
Publicado: (2015)

ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients
por: Li, Ziyu, et al.
Publicado: (2016)

Association between Genetic Polymorphism of GSTP1 and Toxicities in Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
por: Kim, Woorim, et al.
Publicado: (2022)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Frequency of NAT2 and GSTP1 polymorphisms in the Kazakh population
por: Iskakova, Aisha, et al.
Publicado: (2014)

PB2066: THE STUDY OF GSTP1 AND MDR1 GENES POLYMORPHISMS IN HODGKIN’S LYMPHOMA AND THEIR LINK WITH CHEMOTHERAPY RESPONSE.
por: Voytko, M., et al.
Publicado: (2022)

Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity
por: Wu, Shouquan, et al.
Publicado: (2016)

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
por: Wagner, A D, et al.
Publicado: (2009)

CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients
por: Yang, Lin, et al.
Publicado: (2017)

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017)

A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer
por: Wang, Qinchuan, et al.
Publicado: (2020)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells
por: Gonçalves-Ribeiro, Samuel, et al.
Publicado: (2016)

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
por: Sun, Xianjun, et al.
Publicado: (2020)

Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial
por: Yu, Jiren, et al.
Publicado: (2022)

Chemotherapy regimen based on sorafenib combined with 5-FU on HIF-1α and VEGF expression and survival in advanced gastric cancer patients
por: Cheng, Ronghui, et al.
Publicado: (2017)

Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy
por: Geng, Ruixuan, et al.
Publicado: (2014)

Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
por: Glatz, Torben, et al.
Publicado: (2020)

Genetic Polymorphism of GSTP1, GSTM1 and GSTT1 Genes and Susceptibility to Chronic Myeloid Leukaemia
por: Idris, Hadeil ME, et al.
Publicado: (2020)

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer
por: Ferracini, Amanda Canato, et al.
Publicado: (2020)

Association among genetic polymorphisms of GSTP1, HO-1, and SOD-3 and chronic obstructive pulmonary disease susceptibility
por: Du, Yong, et al.
Publicado: (2019)

GSTM1, GSTT1 and GSTP1 Polymorphisms in the Korean Population
por: Cho, Hyun-Jung, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_65f88ta1cv4395pfoasn78e57o